SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Acceleron Pharma Announces the Initiation of the Gynecologic Oncology Group Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients With Endometrial Cancer
Your Message